FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
Marks First Approval for KEYTRUDA in SCLC KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE:MRK), known as MSD outside the United States and…